Rank |
Status |
Study |
1 |
Recruiting
|
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
Conditions: |
Tremor; Essential Tremor; Parkinson Disease; Radiosurgery; Quality of Life |
Intervention: |
|
Outcome Measures: |
Quality of Life; Severity of Tremor |
|
2 |
Not yet recruiting
|
Limb Cooling in Essential Tremor
Condition: |
Essential Tremor. |
Intervention: |
Procedure: Limb Cooling Assessment of ET |
Outcome Measures: |
Hand writing assessment battery on limb cooling at 60 minutes post-cooling; Tremor rating scale on limb cooling at 40 minutes post-cooling; Functional dexterity test on limb cooling at 60 minutes post-cooling; Hand writing assessment battery on limb cooling at 15 minutes post-cooling; Hand writing assessment battery on limb cooling at 40 minutes post-cooling; Tremor rating scale on limb cooling at 15 minutes post-cooling; Functional dexterity test on limb cooling at 15 minutes post-cooling; Functional dexterity test on limb cooling at 40 minutes post-cooling; Tremor rating scale on limb cooling at 60 minutes post-cooling; Effect of limb cooling on the physiological characteristics of essential Tremors. |
|
3 |
Recruiting
|
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Conditions: |
Essential Voice Tremor; Vocal Tremor; Voice Tremor; Essential Tremor of Voice |
Intervention: |
Drug: Octanoic acid |
Outcome Measures: |
Pre- to post-treatment change in the acoustic characteristics of voice tremor; Pre- to post-treatment change in the auditory-perceptual characteristics of voice tremor |
|
4 |
Not yet recruiting
|
The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study
Conditions: |
Essential Tremor; Parkinson Disease |
Intervention: |
Procedure: Stimulation procedure |
Outcome Measures: |
The severe adverse events rate within the procedure; Improvement in tremor symptoms during the procedure |
|
5 |
Not yet recruiting
|
Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
Condition: |
Essential Tremor |
Intervention: |
Device: Cathodal cerebellar transcranial direct current stimulation |
Outcome Measures: |
Change from baseline in tremor amplitude on clinical rating scale; Change from baseline in tremor amplitude on accelerometric recording; Change from baseline in tremor amplitude on electromyographic recordings; Change from baseline in tremor amplitude on digitized tablet; Change from baseline of amplitude of motor evoked potentials elicited by TMS |
|
6 |
Recruiting
|
Continuous Tremor Assessment During Daily Activities
Condition: |
Essential Tremor |
Intervention: |
Device: Kinesia HomeView |
Outcome Measures: |
Clinical Global Impression-Change Scale score; Clinical Global Impression-Severity Scale Score; Washington Heights Inwood Genetic Study of Essential Tremor (WHIGET) Tremor Rating Scale; Quality of Life in Essential Tremor Questionnaire |
|
7 |
Recruiting
|
Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor
Conditions: |
Parkinson's Disease; Tremor |
Interventions: |
Device: Up to 3 mA, 60 us, 130 Hz deep brain stimulation; Device: Empirical unblinded deep brain stimulation programming |
Outcome Measures: |
Change from baseline United Parkinsons Disease Rating Scale Part III at 3 months; Change from baseline United Parkinsons Disease Rating Scale Part III at 6 months; Change from baseline United Parkinsons Disease Rating Scale Part III at 12 months; Change from baseline Fahn Tolosa Marin tremor scale at 3 months; Change from baseline Fahn Tolosa Marin tremor scale at 6 months; Change from baseline Fahn Tolosa Marin tremor scale at 12 months; Change from baseline ON-OFF diary at 3 months; Change from baseline ON-OFF diary at 6 months; Change from baseline ON-OFF diary at 12 months; Adverse events; Change from baseline Short form 36 at 3 months; Change from baseline Short form 36 at 6 months; Change from baseline Short form 36 at 12 months; Change from baseline Parkinsons Disease Quality of Life 39 at 3 months; Change from baseline Parkinsons Disease Quality of Life 39 at 6 months; Change from baseline Parkinsons Disease Quality of Life 39 at 12 months; Change from baseline L-dopa equivalent dose at 3 months; Change from baseline L-dopa equivalent dose at 6 months; Change from baseline L-dopa equivalent dose at 12 months; Change from baseline neuropsychological battery at 3 months; Change from baseline neuropsychological battery at 6 months; Change from baseline neuropsychological battery at 12 months; Change from baseline verbal fluency at 3 months; Change from baseline verbal fluency at 6 months; Change from baseline verbal fluency at 12 months; Change from baseline Mini-International Neuropsychiatric Interview Plus at 3 months; Change from baseline Mini-International Neuropsychiatric Interview Plus at 6 months; Change from baseline Mini-International Neuropsychiatric Interview Plus at 12 months; Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 3 months; Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 6 months; Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 12 months; Change from baseline Abnormal Involuntary Movement Scale at 3 months; Change from baseline Abnormal Involuntary Movement Scale at 6 months; Change from baseline Abnormal Involuntary Movement Scale at 12 months |
|
8 |
Recruiting
|
Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor
Conditions: |
Parkinson's Disease; Essential Tremor |
Intervention: |
|
Outcome Measures: |
Fractional anisotropy (FA) in the caudal portion of substantia nigra; Comparison between MRI and ultrasonography |
|
9 |
Unknown †
|
Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
Condition: |
Essential Tremor |
Interventions: |
Drug: pramipexole; Drug: placebo |
Outcome Measures: |
Improvement in tremor severity; Improvement in quality of life; Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
|
10 |
Recruiting
|
Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates
Condition: |
Essential Tremor |
Intervention: |
|
Outcome Measures: |
Phase 1: To objectively determine the rate of ethanol responders vs. non-responders in a prospective sample of ET patients.; Phase 2: To evaluate changes of SICI in responding vs. non-responding ET patients during a continuous ethanol administration; Phase 1: To correlate spirographic and clinical response in both hands with breath-alcohol-levels, acquired using a Breathalyzer at constant intervals after ethanol administration.; Phase 2: To evaluate changes additional TMS measures between groups |
|
11 |
Unknown †
|
The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
Conditions: |
Multiple Sclerosis; Tremor |
Intervention: |
Drug: Botulinum Toxin Type A |
Outcome Measures: |
A decrease in tremor; The safety profile of Botulinum Toxin in MS patients |
|
12 |
Recruiting
|
Assessment of Tremor Using SNUMAP Motion Sensing System
Condition: |
Tremor |
Intervention: |
Device: SNUMAP |
Outcome Measure: |
3-D Accelerometric and gyroscope variables measured |
|
13 |
Recruiting
|
Radiosurgery for Drug Resistant Invalidating Tremor
Condition: |
Severe Upper Limb Tremor Refractory to Medical Therapy |
Intervention: |
Radiation: Radiosurgical thalamotomy |
Outcome Measures: |
Tremor control (improvement in FTMTRS and/or UPDRS motor); Targeting methodology validation (the lesions position, if present, will be compared to the treatment plan target position, deviations will be registered).; The treatment safety will be evaluated. Toxicity will be registered according to NCI-CTCAE v3. |
|
14 |
Recruiting
|
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
Condition: |
Essential Tremor |
Interventions: |
Device: Transcranial ExAblate; Device: Sham Transcranial ExAblate |
Outcome Measures: |
Severity of Device and Procedure related complications; Effectiveness of of the ExAblate Transcranial MRgFUS treatment |
|
15 |
Recruiting
|
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Conditions: |
Spasmodic Dysphonia; Voice Tremor |
Intervention: |
Drug: Sodium oxybate |
Outcome Measure: |
Brain Activity |
|
16 |
Unknown †
|
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
Condition: |
Parkinsonian Syndromes |
Intervention: |
Drug: 123 I - ALTROPANE® |
Outcome Measures: |
To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.; To evaluate the safety of 123 I-ALTROPANE® in subjects with upper extremity tremor for less than 2 years. |
|
17 |
Recruiting
|
Deep Brain Stimulation Surgery for Movement Disorders
Conditions: |
Parkinson's Disease; Essential Tremor; Dystonia |
Intervention: |
Procedure: Deep Brain Stimulation |
Outcome Measures: |
Change in UPDRS III scale, Burke-Fahn-Marsden (BFM) scale, and Tremor Rating Scale before and 1 year after treatment.; Levels of effective drug therapy before/after surgery; Radiographic correlation of DBS electrode position and clinical changes; Neurophysiological mechanisms of DBS and motor/cognitive function in basal ganglia |
|
18 |
Not yet recruiting
|
Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes
Conditions: |
Parkinson's Disease; Essential Tremor; Dystonia |
Intervention: |
|
Outcome Measure: |
Recording and evaluating LFPs from DBS electrodes in patients with Parkinson's Disease, Essential Tremor or Dystonia |
|
19 |
Recruiting
|
Cannabis and Parkinson's Disease Tremor: A Natural History Study
Condition: |
Parkinson's Disease |
Intervention: |
|
Outcome Measure: |
Percent reduction in tremor as measured by Opal movement sensor |
|
20 |
Recruiting
|
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: |
Essential Tremor; Multiple System Atrophy; Corticobasal Degeneration; Supranuclear Palsy, Progressive |
Intervention: |
|
Outcome Measures: |
Focal oscillatory activity; Spectral coherence:; Spectral Granger analysis:; Reactivity:; Complex network analysis: |
|